Arca
Skip to content
Tools
Tools

T-cell lymphoma

Drug research and approvals for T-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 539 studies of T-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, FDA has 12 approved and 61 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 539
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 12
  • EU medicines: 2

Recruiting now

Newest posted first, of 539 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 14

Phase 3 12 of 22

  • CyclophosphamidePeripheral T-cell lymphoma · DNA inhibitor
  • DoxorubicinPeripheral T-cell lymphoma · DNA topoisomerase II alpha inhibitor
  • TucidinostatPeripheral T-cell lymphoma
  • VincristinePeripheral T-cell lymphoma · Tubulin inhibitor
  • AzacitidinePeripheral T-cell lymphoma · DNA (cytosine-5)-methyltransferase 3A inhibitor
  • GemcitabinePeripheral T-cell lymphoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
  • AlemtuzumabPeripheral T-cell lymphoma · CAMPATH-1 antigen inhibitor
  • CisplatinPeripheral T-cell lymphoma · DNA inhibitor
  • MitoxantronePeripheral T-cell lymphoma · DNA topoisomerase II alpha inhibitor
  • HypericinMycosis fungoides
  • DecitabinePeripheral T-cell lymphoma · DNA (cytosine-5)-methyltransferase 3A inhibitor
  • DacarbazinePeripheral T-cell lymphoma · DNA inhibitor

Phase 2 12 of 75

  • LenalidomidePeripheral T-cell lymphoma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
  • PembrolizumabMycosis fungoides · Programmed cell death protein 1 inhibitor
  • CytarabineAnaplastic large-cell lymphoma · DNA inhibitor
  • PanobinostatCutaneous T-cell lymphoma · Histone deacetylase inhibitor
  • RituximabAnaplastic large-cell lymphoma · B-lymphocyte antigen CD20 binding agent
  • NivolumabPeripheral T-cell lymphoma · Programmed cell death protein 1 inhibitor
  • TanespimycinAnaplastic large-cell lymphoma · Heat shock protein HSP90 inhibitor
  • DarinaparsinPeripheral T-cell lymphoma
  • BusulfanDNA inhibitor
  • Mycophenolate mofetilSezary syndrome · Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
  • TacrolimusSezary syndrome · FK506-binding protein 1A inhibitor
  • VinorelbineAnaplastic large-cell lymphoma · Tubulin inhibitor

Phase 1 or earlier 12 of 42

  • CarfilzomibPeripheral T-cell lymphoma · 26S proteasome inhibitor
  • AgatolimodMycosis fungoides · Toll-like receptor 9 agonist
  • DurvalumabCutaneous T-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
  • ParsaclisibPeripheral T-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
  • GuanineCutaneous T-cell lymphoma
  • 6-O-benzylguanineCutaneous T-cell lymphoma
  • LinperlisibPeripheral T-cell lymphoma
  • CarboplatinAnaplastic large-cell lymphoma · DNA inhibitor
  • CyclosporineSezary syndrome · Cyclophilin A modulator
  • IrinotecanAnaplastic large-cell lymphoma · DNA topoisomerase I inhibitor
  • TrastuzumabMycosis fungoides · Receptor protein-tyrosine kinase erbB-2 inhibitor
  • AldesleukinSezary syndrome · Interleukin-2 receptor agonist

How its trials ended

775 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 214 whose ending is known, 34% met their primary endpoint, 7% missed it and 59% stopped early.

  • Completed, result not reported21928%
  • Ongoing20627%
  • Status unknown13618%
  • Met its primary endpoint739%
  • Stopped: other or unclear517%
  • Stopped: enrollment or feasibility385%
  • Stopped: sponsor or business decision213%
  • Missed its primary endpoint142%
  • Stopped: funding71%
  • Stopped: lack of efficacy61%
  • Stopped: safety41%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 18, 2022An interventional, single-arm, open-label phase II study investigating the efficacy and safety of ANTI-PD1 immunotherapy for the treatment of patients with…Libtayo (cemiplimab)Alberta Health Services, Cross Cancer InstitutePending
Feb 6, 2019An open-label, multi-center extension study to investigate the efficacy and safety of cobomarsen (MRG-106) following systemic treatment, in subjects with ctcl,…Cobomarsen / Fludeoxyglucose 18FMiragen TherapeuticsPending
Aug 1, 2018Solar: a phase 2, randomized, open-label, parallel-group, active comparator, multi-center study to investigate the efficacy and safety of cobomarsen (MRG-106)…CobomarsenMiragen TherapeuticsOngoing
May 24, 2016A phase I trial of MEDI-570 in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) follicular variant and angioimmunoblastic T-cell lymphoma…MEDI-570 / GlucovisionPrincess Margaret Hospital Phase I ConsortiumClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 73
Aug 7, 2024LymphirTreatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic…Citius Oncology, Inc.Approved
Nov 16, 2018AdcetrisADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including…Seagen Inc.Approved
Aug 8, 2018PoteligeoPOTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after…Kyowa Kirin Pharmaceutical Development Inc.Approved
Jul 3, 2014BeleodaqTreatment of patients with relapsed or refractory peripheral T-cell lymphomaAcrotech Biopharma LLCApproved
Aug 23, 2013ValchlorTopical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed…Helsinn Birex Pharmaceuticals Ltd.Approved
Aug 19, 2011AdcetrisThe treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy…Seagen Inc.Approved
Jun 16, 2011IstodaxTreatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapyCelgene CorporationApproved
Nov 5, 2009IstodaxTreatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapyCelgene CorporationApproved
Sep 24, 2009FolotynTreatment of patients with relapsed or refractory peripheral T-cell lymphomaAcrotech Biopharma LLCApproved
Oct 6, 2006ZolinzaTreatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent…Merck & Co., Inc.Approved
Dec 29, 1999TargretinTreatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.Eisai, Inc.Approved
Feb 5, 1999OntakTreatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2…Eisai, Inc.Approved
Sep 8, 2026Peginterferon alfa-2aTreatment of T-cell lymphomapharmaand GmbHDesignated
Apr 13, 2026A small molecule inhibitor of Zeste homolog 2 (EZH2)Treatment of T-cell lymphomaEvopoint Biosciences USA, Inc.Designated
Sep 12, 2025Allogeneic chimeric antigen receptor (CAR) T-cell therapy…Treatment of T-cell lymphomaNanjing Miracle Biotechnology Co., Ltd.Designated

Medicines authorised in the EU

Newest first
Mar 3, 2017LedagaChlormethine · orphanHelsinn Birex Pharmaceuticals Ltd.EMA ↗
Mar 29, 2001TargretinBexaroteneH.A.C. PharmaEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.